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Aldosterone, the most potent of the mineralocorticolds 
secreted by the adrenal cortex, plays a prominent role in the 
regulation of water and electrolyte metabolism in normal and in 
certain pathological states. Since many features of its biological 
activity are as yet incompletely understood, the utilization of 
a compound capable of reversing or antagonizing its effect would 
provide a convenient investigative tool. In 1957 Kagawa et al. 
( 1 ) reported that a synthetic steroidal spirolactone SC-5233 or 
its 19-nor analogue SC-8109 reversibly blocked the renal tubular 
effects of desoxycorticosterone acetate in adrenalectomized rats 
whereas neither of the spirolactones affected urinary electrolytes 
by itself. Recently Liddle ( 2 ) reported that SC-8109 reverses the 
renal tubular effects of aldosterone or biologically similar 
steroids such as DOCA in human subjects. In addition he reported 
that when patients with Addison’s disease were maintained on a 
high sodium diet without steroid therapy, the administration of 
spirolactone had little or no effect on urinary electrolytes. 
These same patients maintained on a high sodium diet plus DOCA 
responded to spirolactone in a manner simulating the abrupt with¬ 
drawal of the renal effects of aldosterone. On the basis of these 
findings it has been suggested that spirolactone blocks the renal 
tubular effects of aldosterone. 
The present investigation was designed to determine whether 
spirolactone’s effect of reducing aldosterone activity is limited 
to the kidney. 
J 
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MATERIALS AND METHODS 
Sub jects 
Three patients with Laennec Ts cirrhosis and intractible 
ascites were studied. In each case the diagnosis was histologically 
established by liver biopsy performed prior to the investigation. 
One patient was studied on two occasions separated by a period of 
8 months. To distinguish between these, they will be designated 
AC-I and AC-II and will be considered separately in the text. 
Pertinent clinical findings are recorded in Table 1. In each 
case the history revealed heavy alcholic intake and poor dietary 
habits. In all three patients previous treatment with bed rest, 
low sodium diet (10 mEq. per day), mercurial diuretics, and 
chlorthiazide had been ineffective in bringing about sodium and 
water loss. In addition RO had received a prior course of intra¬ 
venous albumin with no resultant change in weight. None had 
other significant illness or evidence of gastro-intestinal bleeding. 
Program of study 
Each subject was placed on a diet which included a daily intake 
of 10 mEq. of sodium, 23>00 calories, and from 60 to 80 grams of 
protein. Potassium intake was not regulated, but no potassium 
other than that contained in the diet was given. There was no 
restriction of fluid Intake. 
Daily Z\\ hour urine specimens were collected under mineral 
oil with thymol crystals added as a preservative. The subjects 
were weighed at the same time each day. Urine volume was recorded 




Saliva specimens were obtained at the same time each day in 
the following manner: after washing his mouth out with water, the 
subject chewed a piece of paraffin, expectorating all saliva into 
a sodium and potassium free container until 7 cc. were obtained. 
Serum sodium, potassium, chloride, and bicarbonate concentrations 
were determined twice during the control period and at suitable 
intervals throughout the study. 
The subjects were observed carefully for any signs of drug 
toxicity, including changes in vital signs, gastro-intestinal 
function, and mental status. The skin was examined for any changes, 
especially at the site of injection. 
Blood samples from each subject were analyzed before and after 
administration of the drug to detect any changes in hematocrit, 
white blood cell count, serum proteins, liver function tests, 
and either blood urea nitrogen or non-protein nitrogen. 
After a 3-d.ay control period each subject was given a 1-day 
course of SC-8109 administered in 8 divided doses given every 
3 hours. In studies in which more than 1 dosage range was used, 
a subsequent dose was not administered until urinary excretion of 
sodium had returned to the control level. 
The dosages and routes of administration of the drug are 
recorded in Table 2. AG became hyponatremic (serum sodium 
z 120 mEq./liter) during the first study period following an 
intramuscular dose of 800 mg. and was treated with 20 gms. of 
NaCl by mouth and restriction of fluid intake over a period of 
6 days at the end of the study (Fig. 1). 

k 
Me thod s 
Urinary, salivary, and serum sodium and potassium were determined 
on a Patwin flame photometer. Urinary ammonium was analyzed by the 
micro-diffusion method of Conway; titratable acidity by the method of 
Henderson and Palmer (3)? and pH on a Cambridge electron ray pH 
meter. Serum chloride was determined by the method of Schales and 
Schales (4) and bicarbonate by the method of Van Slyke and Neill (5)* 
RESULTS 
The results of the studies are illustrated in Figs. 1-4* 
Effects on urinary sodium and potassium 
On the day of administration of SC-8109 urinary sodium excretion 
generally rose above the control levels of 1 to 5 mEq. per day and 
then fell slowly to control levels. Two exceptions to this pattern 
were noted: in AC-II (Fig. 2) the rise continued for four days, at 
which time the study was discontinued; and in DS (Fig. 3) the 100 mg. 
dose had no demonstrable effect. The greatest 24 hour sodium excre¬ 
tion attained by the three subjects receiving the 800 mg. intramuscular 
dose was between 37 and 49 mEq. (Figs. 1, 3> and 4)« 
In no subject was urinary potassium significantly increased by 
the administration of SC-8109, and in AC-II there was a sizable 
decrease following drug administration. The rise in Na/K ratio 
roughly paralleled sodium excretion, and in both studies of AC a 
concomitant decrease in potassium excretion augmented the effect of 
the increased sodium loss on the ratio. 
Na/K ratios rose to a level between 4 and 6 times control values 
after administration of the 800 mg. dose. The highest ratio reached, 
1.3, was in the first study of AC following the administration of 
400 mg. intramuscular dose. 
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Effect on urinary hydrogen ion 
AC-I and RO excreted decreased amounts of titratable acid 
for 3 and 4 days respectively following the administration of SC-8109* 
There was a concomitant small decrease in ammonium excretion in 
RO and a rather large decrease for 1 day in AC. Urinary pH rose 
in RO from a control level of about 6.0 to a level of 6.8 three 
days after the administration of the drug, and in AC-I from 6.4 
to 7.0 four days after administration. 
The drug had no significant effect on urinary pH, titratable 
acidity, or ammonium in DS. The increased urinary ammonium and 
pH and decreased titratable acidity noted on day 6, three days 
after DS received a 100 mg. parenteral dose of SC-8109, coincided 
o 
with an elevation of temperature to 101 P. The hydrogen ion 
changes were attributed to a transient urinary tract infection, 
but this was not definitely established. 
Effect on urine volume 
In general, parenterally administered SC-8109 had a much less 
dramatic effect on urine volume than comparable doses given orally. 
Parenteral administration of 800 mg. SC-8109 raised the urinary 
volume by an average of 175 cc. for a period of 4 or 5 days. This 
was in striking contrast to the effects of an 800 mg. oral dose, 
which increased the urine volume by more than a liter a day for a 
period of two days (see '’Comparison of dose and route”). 
Effect on the saliva 
Salivary sodium and potassium studies were carried out on all 
3 subjects. A significant change occurred in one, and there was a 
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Salivary Na/K ratios rose on the day of administration of all 
doses to DS, the most significant rise occurring after the 800 mg. 
oral dose when the ratio rose from 0.35 to 0.55* The changes in 
ratio were usually due to both increased sodium and decreased 
potassium concentrations, but the 0.55 value was due to a significant 
decrease in potassium. 
In the first study of AC, the salivary Na/K ratio rose to its 
highest level, O.36, the day after administration of [j_00 mg. 
intramuscular dose. There was no significant change after the 
800 mg. dose, but at that time her serum sodium was depressed, and 
this may have affected the salivary sodium concentration. 
Effect on Weight 
In subjects AC-I and R0 there was a significant loss of 
weight within one or two days following the administration of 
SC-8IO9. RO lost 0.7 kilos following a 800 mg. parenteral dose 
and AC-I lost 0.8 kilos following a 400 mg. dose by the same route. 
Oral administration of 800 mg. to DS was followed by a leveling-off 
and slight reversal of a previously relentless weight increase. 
Weight changes may have been obscured in some of the studies by 
the uncontrolled fluid intake. 
Comparison of dose and route 
Response to SC-8109 appeared to be affected by the size of 
the dose and the route of administration. 
In general It was found that the greater the dose administered 
the greater the response. This was exemplified by the response of 
DS, in terms of sodium excretion, to 100, ipOO, and 800 mg. parenteral 
•' ' • 
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doses; no increase with the first, very small but significant in¬ 
crease with the second, and a relatively large increase with the 
third (Pig. 3)« 
Similarly AC-I had a greater response to I|.00 mg. than to 
100 mg.jhowever there was no further increase in response to 800 mg. 
This was most likely due to the decrease in serum sodium, the 
resultant decrease in filtered load of sodium causing a decrease 
in the amount delivered to the tubules. The subject may also have 
been secreting a greater quantity of aldosterone as a response to 
the lowering of the serum sodium. 
Oral and parenteral dose responses can be compared in DS. 
The oral dose resulted in a more abrupt rise and fall in urinary 
sodium excretion with a higher peak. Maximal effect was noted on 
the first day with the oral dose and on the second day with the 
intramuscular dose. The peak effect of an 800 mg. dose administered 
orally was a sodium excretion of 44 mEq. per day; that of 800 mg. 
given parenterally an excretion of 30 mEq. per day. Whereas it 
took only 3 days following the oral dose for urinary sodium excretion 
to return to control levels, it took 6 days following the parenteral 
dose. The total quantity of sodium lost after treatment by the 
two routes was approximately equal. More marked effects on salivary 
electrolytes occurred after 800 mg. given orally than after a 
comparable intramuscular dose. 
Side effects 
There was no change in vital signs or mental status in any of 
the subjects, and there was no significant change in blood urea 
nitrogen, non-protein nitrogen, serum proteins, or liver function 
tests 
* I 
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No reaction or discomfort at the site of injection was 
encountered. 
DS had a nose bleed on the day he received the I4.OO mg. 
intramuscular dose. Platelet counts done that day were over 
3 
200,000 per mm , and prothrombin time was 26% of normal. The 
prothrombin level during the control period was $5%. Fifty mg. 
of Vit. K-^ were given, and the prothrombin level rose above l±5%» 
AC, in whom long-standing esophageal varices had been 
demonstrated by X-ray, had experienced intermittent gastro¬ 
intestinal disturbances for over a year prior to this investigation. 
The second study of this subject was discontinued I4. days after 
administration of SC-8109 because of an exacerbation of those 
complaints, and the following day the patient bled from esophageal 
varices. In view of the antecedent complaints and the previous 
demonstration of varices, it is unlikely that these symptoms were 
due to the drug. 
The hyponatremia encountered in AC was a disturbing complica¬ 
tion of treatment. Serum sodium fell in both studies; during the 
first period (Fig. 1) this was associated with a decrease in all 
other serum electrolytes; during the second period (Fig. 2) 
the other electrolytes were unaffected. In the first instance 
the hyponatremia was probably the result of urinary salt depletion 
complicated by serum dilution related to uncontrolled water intake. 
Strict fluid restriction and an oral intake of 20 gms. of NaCl over 
a period of 6 days following the first study brought the serum 
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DISCUSSION 
Patients with cirrhosis who are accumulating ascites have 
been found to excrete in their urine only a small fraction of 
the sodium they ingest. This avid sodium retention, manifested 
not only in the urine but also in saliva, sweat, and feces, is 
associated regularly with greatly elevated urinary levels of the 
sodium-retaining hormone, aldosterone (7). Both of these findings 
reflect, presumably, increased secretion and activity of the 
hormone. 
Postulating that decreased activity of aldosterone might 
halt the fluid retention, Marson ( 8 ) and Guiseffi et al. ( 9 ) 
performed total adrenalectomies on patients with cirrhosis and 
intractible ascites, achieving significant but incomplete diuresis 
and sodium loss. 
Amphenone, which inhibits the biogenesis of several adreno¬ 
cortical hormones including aldosterone, has been used to the same 
end (10). Its usefulness, however, is limited by its toxicity. 
The synthetic steroidal spirolactone SC-8109 is reported to 
be active only in the presence of elevated levels of endogenous 
or exogenous aldosterone or biologically similar steriods, blocking 
their renal tubular actions competitively. In this study the 
effects of this compound on electrolyte and water metabolism in 
different end organ sites of aldosterone activity were investigated. 
With both oral and parenteral administration of SC-8109 there 
was a marked increase in the urinary Na/K ratio. It Is evident that 
because of the small amounts of urinary sodium excreted during the 
control periods, an approximately equal increase in both sodium 
and potassium excretion would result in a significant increase in 
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the Na/K ratio. This has been observed following the administration 
of diuretics such as mercurials or carbonic anhydrase inhibitors ( 2 ). 
More significant here is the fact that increased Na/K ratios occurred 
in the absence of any increase in potassium excretion; there is a 
suggestion that potassium excretion was actually decreased following 
the administration of the compound in two of the subjects. 
Two studies indicated that even at the time of maximal 
sodium and water diuresis, hydrogen ion excretion, as measured by 
urinary pH, ammonium, and titratable acidity, was decreased. There 
was no observed effect on urinary hydrogen ion in one of the subjects. 
Thus, there was increased sodium excretion and either decreased 
or unchanged potassium excretion on all three subjects and decreased 
hydrogen ion excretion in two of these. Since the renal effect of 
aldosterone is to decrease sodium excretion and to increase 
potassium and hydrogen ion excretion (1 ), the urinary electrolyte 
findings reported here are consistent with the view that SC-8109 
inhibits the activity of aldosterone in the kidney. 
Aldosterone decreases sodium and/or increases potassium 
concentration in saliva, sweat, and feces as well as in the 
urine (11). To test the hypothesis that the administration of 
SC-8109 results in decreased aldosterone activity throughout the 
body, studies of salivary sodium and potassium were carried out. 
Certain diuretics such as the mercurials raise the urinary Na/K 
ratio but have no effect on the salivary electrolytes. In contrast, 
SC-8IO9 caused a change in the salivary Na/K ratio in 2 of the 3 
subjects studied which was consistent with a decrease in aldosterone 
activity. 
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Decreased aldosterone activity could be brought about in a 
number of ways, including decreased secretion, increased urinary 
losses and/or increased inactivation, as well as by competitive 
inhibition. The exact mechanism of action of SC-8109 cannot be 
determined from the data available at present. Certain inferences 
can be made, however. 
The fact that the compound is active in adrenalectomized 
animals given desoxycorticosterone acetate or aldosterone indicates 
that its mechanism is not primarily supression of secretion. 
Indeed, Bolte et al. (12) found that in 2 patients with cirrhosis 
urinary excretion of aldosterone rose eight times above the control 
level following, the administration of SC-8109, a finding presum¬ 
ably due to increased secretion. It is unlikely that spirolactone 
acts by increasing losses of aldosterone in the urine, in view of 
Leutcher’s findings that the compound blocked the action of 
aldosterone in a patient with nephrosis without changing urinary 
aldosterone. The relationship between aldosterone secretion and 
urinary excretion is somewhat obscured by the fact that urinary 
aldosterone as now measured by chromatographic methods represents 
only 5 to 10% of the daily secretion (13). 
The most probable action of spirolactone remains that of 
competitive inhibition at the end organ site of aldosterone activity. 
However the remote possibility that it acts by increasing inactiva¬ 
tion of the hormone cannot be excluded. 
The finding of this study suggest that SC-8109 may be of thera¬ 
peutic value in patients with cirrhosis and ascites. The compound 
has the advantage of inducing a sodium and water diuresis without 
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diuretics, hyponatremia must be considered a possible hazard. Whether 
spirolactone is effective and free of toxic effects when given over 
a long period remains to be seen. 
SUMMARY AND CONCLUSIONS 
Pour studies were carried out on cirrhotics with intract- 
ible ascites, presumably associated with increased aldosterone 
activity, to determine whether the synthetic steroidal 
spirolactone SC-8109 reduces this activity in the kidney and 
salivary glands. 
The effects of the compound on urinary electrolytes were 
consistent with a decreased aldosterone effect in the kidney in 
all the subjects studied. 
Its effects on salivary electrolytes were consistent with a 
decreased aldosterone effect in one subject and suggestive of 
this in another. 
The reduction of aldosterone activity brought about by 
SC-8109 thus is not limited to the renal tubule. 
The most probable mechanism of action of SC-8IO9 is 
competitive inhibition of aldosterone activity at its site of 
action in the tissues. 







INITIAL CLINICAL AND LABORATORY FINDINGS 
Patient DS AC-I AC-II RO 
Age and sex 56 yr. M 69 yr. F 70 yr. F 67 yr. M 
Ascites 
Severity 4/ 2/ 3/ 3/ 
Duration 3 yr. 6 mo. 1 yr. 3 mo. 
Pedal edema none none 1/ none 
Serum Na (mEq/Liter) 139 133 llil 141 
Serum K (mEq/liter) 4-5 4.7 44 4.5 
Total protein (gm.%) 6.1 6.9 5*5 6.7 
Alb./Glob. (gm.$) 2.7/34 2.1/4.8 1.6/3.9 2.9/3.8 
Total bilirubin (mg.%) 1.32 1.26 1.28 1.38 
Bromsulphalein retention (%) 3,0 o2% iW -- 32% 
Blood urea N. (mg. %) 23 -- -- 25 
Non-protein N. (mg. %) — 34 33 -- 
» f J 
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DOSE A ED ROUTE OF ADMINISTRATION OF SC-8109 
Intramuscular Oral 
100 mg. 400 mg. 800 mg. 1|00 mg. 800 1 
AC-I (Fig. 1) X X X 
AC - II (Pig. 2) X 
DS (Pig. 3) X X X X X 
RO (Fig. 4) X 
ll I 
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